MedTrace Logo

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

NCT02294058 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1346

Last updated 2020-11-25

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether ozanimod is effective in the treatment of relapsing multiple sclerosis (RMS).

Conditions

Interventions

DRUG

Ozanimod

Capsules for oral administration once a day

DRUG

Interferon beta-1a

Administered by intramuscular injection once a week

DRUG

Placebo to ozanimod

Matching placebo capsules administered orally once a day

DRUG

Placebo to interferon beta-1a

Placebo intramuscular injection once a week

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • James Sheffiled, MD · Celgene

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-03
Primary Completion
2016-12-22
Completion
2016-12-22

Countries

  • United States
  • Belarus
  • Bosnia and Herzegovina
  • Bulgaria
  • Canada
  • Croatia
  • Czechia
  • Estonia
  • Georgia
  • Germany
  • Hungary
  • Latvia
  • Lithuania
  • Moldova
  • Netherlands
  • New Zealand
  • Poland
  • Portugal
  • Romania
  • Russia
  • Serbia
  • Spain
  • Sweden
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02294058 on ClinicalTrials.gov